Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | MPI | P34949 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.42 |
| ▸ | TDP2 | O95551 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5234386 | 0.89 | CYP1A2 (0.45) | MAPTSMN1; SMN2CYP1A2MEN1KMT2A | |
| SCHEMBL1699110 | 0.80 | CYP1A2 (0.50) | MAPTSMN1; SMN2CYP1A2MEN1KMT2A | |
| SCHEMBL29588246 | 0.80 | CYP1A2 (0.50) | MAPTSMN1; SMN2CYP1A2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL1699166 | 0.78 | CYP1A2 (0.49) | MAPTSMN1; SMN2CYP1A2MEN1KMT2A | |
| SCHEMBL699878 | 0.78 | CYP1A2 (0.58) | MAPTSMN1; SMN2CYP1A2MEN1KMT2A | |
| SCHEMBL1185191 | 0.78 | CYP1A2 (0.49) | MAPTSMN1; SMN2CYP1A2MEN1KMT2A | |
| SCHEMBL11020418 | 0.72 | MAP2K1 (0.37) | MAPTSMN1; SMN2MEN1KMT2AGAA | |
| SCHEMBL29572479 | 0.72 | CYP1A2 (0.50) | MAPTSMN1; SMN2CYP1A2MEN1KMT2A | |
| SCHEMBL3794487 | 0.72 | CYP1A2 (0.46) | MAPTSMN1; SMN2CYP1A2MEN1KMT2A | |
| SCHEMBL2357532 | 0.72 | CYP1A2 (0.50) | MAPTSMN1; SMN2CYP1A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107531682-B | Maleate salts of B-RAF kinase inhibitors, crystalline forms, processes for their preparation and their use | 百济神州有限公司 | 2021-05-04 | — | — | CN | claimed |
| EP-0228416-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING AZANAPHTHALENES | SCHERING CORPORATION (US) | 1990-03-21 | — | — | EP | claimed |
| EP-0338010-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF HYPERPROLIFERATE SKIN DISEASE. | SCHERING CORP (US) | 1989-10-25 | — | — | EP | claimed |
| WO-1988004172-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF HYPERPROLIFERATE SKIN DISEASE | SCHERING CORPORATION (US) | 1988-06-16 | — | — | WO | claimed |
| EP-0228416-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING AZANAPHTHALENES. | SCHERING CORP (US) | 1987-07-15 | — | — | EP | claimed |
| WO-1986007537-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING AZANAPHTHALENES | SCHERING CORPORATION (US) | 1986-12-31 | — | — | WO | claimed |
| US-20220213114-A1 | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2022-07-07 | — | — | US | disclosed |
| US-20220213114-A1 | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2022-07-07 | — | — | US | disclosed |
| US-11312723-B2 | Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases | THE ROCKEFELLER UNIVERSITY (US) | 2022-04-26 | — | — | US | disclosed |
| US-11312723-B2 | Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases | THE ROCKEFELLER UNIVERSITY (US) | 2022-04-26 | — | — | US | disclosed |
| US-20200369677-A1 | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2020-11-26 | — | — | US | disclosed |
| US-20200369677-A1 | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2020-11-26 | — | — | US | disclosed |
| EP-3716972-A1 | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | The Rockefeller University (US) | 2020-10-07 | — | — | EP | disclosed |
| WO-1988004172-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF HYPERPROLIFERATE SKIN DISEASE | SCHERING CORPORATION (US) | 1988-06-16 | — | — | WO | disclosed |
| US-4680298-A | Tricyclic anti-allergy and use as anti-inflammatory agents | SCHERING CORPORATION (US) | 1987-07-14 | — | — | US | disclosed |
| CN-86100879-A | Novel process for preparing 1-substituted aryl-1, 4-dihydro-4-oxo-1, 8-naphthyridine derivatives and intermediates thereof | — | 1986-12-17 | — | — | CN | disclosed |
| EP-0021704-B1 | SPIRO-HYDANTOIN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. (US) | 1983-04-27 | — | — | EP | disclosed |
| US-4273775-A | PREVENTION OF OCULAR AND NEURITIC, DIABETIS-ASSOCIATED COMPLICATIONS | PFIZER INC. (US) | 1981-06-16 | — | — | US | disclosed |
| EP-0021704-A1 | Spiro-hydantoin derivatives, process for their preparation and pharmaceutical compositions thereof | PFIZER INC. (US) | 1981-01-07 | — | — | EP | disclosed |
| US-4235911-A | TETRAHYDROQUINOLINE-DERIVED SPIRO-HYDANTOINS, CONTROL OF DIABETIC COMPLICATIONS | PFIZER INC. (US) | 1980-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369677-A1 | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | TFPI, TFPI2, SERPINC1 | MAPT 4590/4885SMN1; SMN2 4537/4885CYP1A2 175/4885 |
| US-11312723-B2 | Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases | TFPI, TFPI2, SERPINC1 | MAPT 4590/4885SMN1; SMN2 4537/4885CYP1A2 175/4885 |
| US-20220213114-A1 | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | TFPI, TFPI2, SERPINC1 | MAPT 4590/4885SMN1; SMN2 4537/4885CYP1A2 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.